Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150

Guggenheim analyst Seamus Fernandez has maintained a Buy rating on MBX Biosciences (NASDAQ: MBX) and raised the price target from $88 to $150. This adjustment reflects a positive outlook on the company's performance.